The significance of placenta growth factor in angiogenesis and clinical outcome of human gastric cancer

Chen, Chiung-Nien; Hsieh, Fon‐Jou; Cheng, Yunn-Ming; Cheng, Wen-Fan; Su, Yi-Ning; Chang, King‐Jen; Lee, Po‐Huang

doi:10.1016/j.canlet.2004.05.020

Cited by 103 publications

(90 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Previous reports suggested that plasma PlGF levels are upregulated and correlated with survival in various cancers (12)(13)(14). Surprisingly, serum PlGF was found to be more useful than VEGFA in predicting worse prognostic features and survival in patients with operable gastric cancer (14) and hepatocellular cancer (30). However, in the current study, VEGFA seems to be more prognostic than PlGF in advanced disease.…”

Section: Discussioncontrasting

confidence: 81%

A new angiogenesis prognostic index with VEGFA, PlGF, and angiopoietin1 predicts survival in patients with advanced gastric cancer

Aktaş

Akbulut²,

Yazıcı³

et al. 2017

Turk J Med Sci

View full text Add to dashboard Cite

Background/aim: The role of angiogenic factors in gastric cancer is not clear. We aimed to assess the role of vascular endothelial growth factor A (VEGFA), angiopoietin 1 (Ang-1), and placental growth factor (PlGF) in the prognosis of patients with advanced gastric cancer.Materials and methods: Thirty consecutive patients treated with a modified DCF (docetaxel, cisplatin, and fluorouracil) regimen were included in the study. The plasma VEGFA, Ang-1, and PlGF levels of the patients before treatment and following two cycles of chemotherapy were measured and evaluated as prognostic factors.Results: Poor performance status and lower Ang-1 levels were correlated with poor overall survival (OS). No significant correlation between VEGFA or PlGF and OS was found. An angiogenesis prognostic index (API) based on the levels of VEGFA, Ang-1, and PlGF was found to be highly correlated with OS. Performance status and API were found as independent prognostic factors for OS. Furthermore, a decrease in VEGFA by 25% from the pretreatment level was also found as a prognostic factor for OS independent of response to DCF regimen. Conclusion:Our results support the use of the new API including VEGFA, Ang-1, and PlGF levels in patients with advanced gastric cancer as a predictor of survival.

show abstract

Section: Discussioncontrasting

confidence: 81%

A new angiogenesis prognostic index with VEGFA, PlGF, and angiopoietin1 predicts survival in patients with advanced gastric cancer

Aktaş

Akbulut²,

Yazıcı³

et al. 2017

Turk J Med Sci

View full text Add to dashboard Cite

show abstract

“…VEGF-A and its receptors have been identified to critically influence tumor-related angiogenesis, in several cancer types, including GC. 10 VEGF-A impact on prognosis has been demonstrated by meta-analysis in different cancers such as hepatocellular 11 and pancreatic cancer. 12 Despite numerous studies, however, the prognostic significance of VEGF expression in GC is still under debate 13e21 and an extensive meta-analysis has been recently published 22 showing that ethnicity is a predictive factor of the effect of VEGF-A on prognosis.…”

Section: Introductionmentioning

confidence: 99%

VEGF-A clinical significance in gastric cancers: Immunohistochemical analysis of a wide Italian cohort

Lastraioli

Boni

Romoli

et al. 2014

European Journal of Surgical Oncology (EJSO)

View full text Add to dashboard Cite

Purpose: The clinical significance of VEGF-A expression in gastric cancer (GC) has been reported with contradicting results. We analyzed the expression and clinical significance of VEGF-A in a wide Italian cohort of GC specimens. Methods: VEGF-A expression was tested by immunohistochemistry in 507 patients with GC of all clinical stages. The impact of VEGF-A on overall survival (OS) was evaluated in conjunction with clinical and pathological parameters. Results: In the Italian cohort we studied VEGF-A was not an independent prognostic factor neither at the univariate nor at multivariate analysis. Conclusions: Although frequently expressed, in our study VEGF-A was not able to discriminate between groups of patients with different risk.

show abstract

“…14 Increased PlGF levels have been described in several conditions including cancer, [15][16][17] cutaneous wound and bone fracture healing, [18][19][20][21] and sickle cell disease.…”

Section: Introductionmentioning

confidence: 99%

Placental Growth Factor in Patients with Decreased Renal Function

et al. 2011

View full text Add to dashboard Cite

Background: Patients with decreased renal function are characterized by high cardiovascular morbidity and mortality due to complications of premature atherosclerosis. Placental growth factor (PlGF) is a proatherogenic cytokine and new biomarker of cardiovascular events. The aim of this study was to determine PlGF levels and describe their relationship to renal function and risk factors of atherogenesis in patients with decreased renal function. Methods: The study group consisted of 114 subjects: 45 patients with various degrees of decreased renal function (CHRI), 31 longterm hemodialysis (HD) patients, and 38 age-matched healthy control subjects. PlGF was assessed immunochemically (enzyme-linked immunosorbent assay) and routine biochemical parameters were measured using standard laboratory methods. Results: PlGF levels were significantly increased in CHRI and HD patients compared to controls (10.5 ± 3.3 pg/mL in CHRI patients and 11.5 ± 3.4 pg/mL HD patients vs. 8.1 ± 1.8 pg/mL in controls, both p < 0.0001). In CHRI patients, PlGF was detectable in the urine, and its urine concentration correlated with its serum levels. In HD patients, PlGF correlated with low-density lipoproteins (r = 0.36, p < 0.05), but was not related to C-reactive protein levels. Higher levels of PlGF were found in CHRI patients with cardiovascular disease, compared with those free of such complication. Conclusions: PlGF levels are increased in patients with decreased kidney function. PlGF is detectable in the urine, and serum and urine levels of PlGF are significantly interrelated. It is higher in CHRI patients with cardiovascular disease. Further studies are required to demonstrate the usefulness and significance of PlGF in patients with chronic kidney disease.

show abstract

The significance of placenta growth factor in angiogenesis and clinical outcome of human gastric cancer

Cited by 103 publications

References 35 publications

A new angiogenesis prognostic index with VEGFA, PlGF, and angiopoietin1 predicts survival in patients with advanced gastric cancer

A new angiogenesis prognostic index with VEGFA, PlGF, and angiopoietin1 predicts survival in patients with advanced gastric cancer

VEGF-A clinical significance in gastric cancers: Immunohistochemical analysis of a wide Italian cohort

Placental Growth Factor in Patients with Decreased Renal Function

Contact Info

Product

Resources

About